Cemiplimab in Japanese patients with advanced non-small cell lung cancer
Cemiplimab demonstrated efficacy in Japanese patients as monotherapy for PD-L1 ≥50% and with chemotherapy irrespective of PD-L1 expression. Overall, cemiplimab demonstrated a favorable benefit-risk profile in Japanese patients.
Authors
- Hidenobu Ishii
- Frank Seebach
- Toshihide Yokoyama (ORCID: https://orcid.org/0000-0002-5595-5010)
- Melissa Mathias (ORCID: https://orcid.org/0000-0001-6026-601X)
- Jean‐François Pouliot (ORCID: https://orcid.org/0000-0002-9125-0456)
- Manika Kaul
- Ki Dong Kim (ORCID: https://orcid.org/0000-0002-7642-1149)
- Yuntong Li (ORCID: https://orcid.org/0000-0002-3071-4333)
- Jayakumar Mani (ORCID: https://orcid.org/0000-0003-3147-0753)
- Satoshi Ikeda (ORCID: https://orcid.org/0000-0001-5203-7911)
- Yuki Sato (ORCID: https://orcid.org/0000-0002-7829-7524)
- Anne Paccaly (ORCID: https://orcid.org/0000-0003-0892-9079)
- Seigo Katakura (ORCID: https://orcid.org/0000-0003-4851-3377)
- Jennifer Visich
- Israel Lowy
- Katsuhiko Naoki (ORCID: https://orcid.org/0000-0002-9637-1388)
- Yasutaka Watanabe (ORCID: https://orcid.org/0000-0002-3679-4864)
- Yoko Tani
- Masahide Oki
Institutions
- Kansai Medical University (JP)
- Regeneron (United States) (US)
- Kanagawa Prefectural Hospital Organization (JP)
- Kurashiki Central Hospital (JP)
- Kurume University Hospital (JP)
- Kitasato University Hospital (JP)
- Saitama Cancer Center (JP)
- Kanagawa Cardiovascular and Respiratory Center (JP)
- Nagoya Medical Center (JP)
- Osaka University Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Kanagawa Cancer Center
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1093/jjco/hyaf160
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Regeneron Pharmaceuticals